the Influence of Prophylactic and Empirical Anti-fungal Treatment in Severe Sepsis Patients With Perforations

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This prospective intended to observe the influence of prophylactic and empirical anti-fungal treatment on Severe Sepsis patients with perforations. With the consent of patients' legal guardian for prophylactic use of antifungal agents, patients were divided into two groups: prophylactic group and Empirical group.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanjing PLA General Hospital
• Treatments: Caspofungin; Fluconazole

Criteria

Inclusion Criteria:

1. age ≥16 years

2. the time between gastrointestinal perforations or anastopmotic leakage(s) after abdominal surgery and entering ICU within 6 hours

3. ICU stay of at least 5 days

4. APACHE Ⅱ score within 24 hours of randomization of 16 or more

5. severe sepsis

6. written informed consent -

Exclusion Criteria:

1. documented fungus before gastrointestinal perforations/anastopmotic leakage(s) ongoing antifungal treatment before the study;

2. fluconazole/caspofungin allergy;

3. pregnant of lactating woman;

4. life expectancy of 48 hours or less. -